Customs Data as Infrastructure in Global Pharma

emma SYSTEMS

Structuring Control Across Brokers, Regions and Regulatory Change

Customs in Pharma is Operational Risk Management

Pharmaceutical companies do not need to be reminded that customs matters. It is embedded in daily operations.

Active ingredients, finished medicines and production equipment move across jurisdictions before reaching patients. Clearance delays affect continuity of supply, working capital and regulatory commitments. Customs is not an administrative afterthought. It sits close to operational performance.

Responsibility remains with the importer. Even when declarations are filed by customs brokers, accountability for classification, origin and declared value rests with the company. Finance relies on accurate duty data, compliance functions depend on consistent origin and tariff treatment, and audit requires traceable and defensible documentation across entities.

In stable environments, established processes may function adequately. As tariff regimes, trade restrictions and reporting requirements evolve, expectations increase. Organisations are required not only to file correctly, but to demonstrate control across entities, products and time periods.

That is why the discussion needs to move beyond documentation. In regulated industries such as pharma, customs data forms part of the organisation's governance architecture. When structured and consolidated across brokers and regions, it supports consistent control and informed decision making. When fragmented, responses become reactive.

Carsten Amtrup

CHIEF COMMERCIAL OFFICER

Emma Systems

Customs Data in a Multi-Disciplinary Environment

In pharmaceutical organisations, customs does not sit within a single function. Logistics manages shipment flow and border clearance. Compliance focuses on regulatory alignment. Finance reconciles duties, VAT and transfer pricing. Sustainability and procurement may rely on origin data for reporting and documentation purposes.

Each function depends on customs data, but often from a different perspective and for different decisions.

At the same time, declarations are typically filed by external customs brokers. Supporting documentation is stored in broker systems, and reporting formats vary by provider and jurisdiction. Internal systems may capture selected elements of declaration data, but rarely the full structured dataset across entities and brokers.

Responsibilities are divided, systems are layered and processes are optimised within individual functions. Over time, customs data becomes distributed across roles, platforms and external partners.

The consequence is that consolidated visibility often depends on manual coordination. Questions that cut across functions, such as duty exposure, classification consistency, origin verification or alignment between customs values and transfer pricing, can require time-consuming data collection and reconciliation.

In stable trade environments, this approach can function adequately. As regulatory requirements expand and volatility increases, the limitations become more visible.

Organisations are expected to understand their customs exposure and demonstrate control across products, brokers and entities without delay.The challenge is therefore not primarily geographic. It lies in how customs data is organised and accessed across functions.



Structured Customs Data Analysis

If customs data supports financial reconciliation, regulatory compliance and supply chain reliability, it must be available in a consistent and analysable format across the organisation.

Structured analysis begins with consolidation. Declaration data from all customs brokers should be accessible in a standardised format, independent of individual broker portals. This includes classification, origin, valuation, duty and tax data, as well as supporting documentation.

Access alone is not sufficient. The data must allow comparison across products, entities and time periods. It should be possible to review classification consistency between markets, assess duty exposure across entities and reconcile declared customs values with financial and transfer pricing data without reconstructing reports manually.

Effective analysis also depends on visibility at declaration level. Customs filings are submitted at line level, where classification, origin and customs value are defined for each product. Without structured access to this detail, internal review is often limited to aggregated totals, which can obscure differences across markets or entities.

When data is consolidated and structured appropriately, regulatory changes can be assessed more systematically. Organisations can identify affected products, review historical treatment and quantify financial impact using documented information rather than estimates.

The difference lies not in the regulatory event itself, but in the organisation’s ability to analyse its exposure without manual reconstruction. Where customs data cannot be analysed systematically, response times increase, reconciliation becomes reactive and senior stakeholders rely on partial information.

Why Line-Level Declaration Data Matters

Customs declarations are submitted at line level. Each product line carries its own tariff classification, declared customs value, origin and duty treatment.

Internal reporting, however, is often structured at entity or shipment level. Summary totals provide financial visibility but do not always reveal how individual product lines are declared across markets.

When analysis relies on aggregated reports, it becomes difficult to compare the treatment of identical or similar products between jurisdictions. Differences in classification, preferential origin usage or declared customs values may not be apparent without examining the underlying line-level data.

In pharmaceutical organisations with broad product portfolios, even small variations can accumulate over time. A product classified under different tariff codes in separate markets may result in different duty exposure. Preferential origin applied inconsistently across entities can affect cost and compliance. Variations in declared customs value may intersect with transfer pricing policies.

Access to structured line-level declaration data enables systematic comparison across products, brokers and entities. It allows organisations to move beyond reviewing totals and instead analyse patterns in how goods are declared.

For regulated industries where documentation and traceability are expected to be defensible, line-level visibility provides a more reliable basis for internal review and external scrutiny.

Emma Compliance: A Structured Layer for Customs Data

Establishing structured customs data analysis requires more than document storage. It requires a system that consolidates declaration data from all customs brokers and makes it available in a consistent format across entities.

Emma Compliance provides this structured layer.

Emma Compliance gathers customs declarations and supporting documentation from all your customs brokers into one independent system. Declaration data is standardised so that classification, origin, valuation, duty and tax information can be analysed across products, entities and time periods.

This enables organisations to review patterns, verify consistency and reconcile customs data with financial and transfer pricing information without extracting reports from separate broker portals.

Emma Compliance does not replace customs brokers or alter operational execution. Customs brokers continue to manage filings and clearance in their respective markets. The platform provides a consolidated data foundation that supports analysis, verification and reporting across functions.

Customs Data as a Deliberate Governance Decision

Pharmaceutical organisations operate in an environment where regulatory expectations, financial scrutiny and supply chain reliability are closely connected.

Customs data sits at the intersection of these areas. It influences duty exposure, transfer pricing alignment, origin compliance and audit readiness. As regulatory frameworks become more data-driven, the importance of structured and consistent declaration data continues to increase.

Managing this effectively is not a question of additional manual review. It is a question of design. Whether customs data is treated as fragmented documentation or as a structured and consolidated dataset has implications for how confidently the organisation can respond to change, scrutiny and internal reporting requirements.

Emma Compliance was developed to provide a structured data foundation that supports this approach. By consolidating declaration data from multiple customs brokers into one independent system, the platform enables pharmaceutical organisations to analyse, verify and document customs activity across entities in a consistent manner.

The objective is not to simplify international trade. It is to operate within its complexity with clarity and control.



Where to go next

Structured customs data is a governance decision. If you are currently reviewing your customs data architecture, we would be pleased to share how Emma Compliance is implemented in global pharmaceutical organisations.

Book a Walkthrough

emmasys.com/compliance
sales@emmasys.com

emma SYSTEMS